Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

December 4, 2015December 4, 2015

RA Patients with Adalimumab Antibodies Not at Higher Risk of Blood Clots

News

Patients with rheumatoid arthritis (RA) who developed antibodies against adalimumab are not at increased risk of a thromboembolic event when compared to patients without these antibodies. These are the results from a study presented during ... Read more

November 18, 2015November 18, 2015

RA Patients Taking Tofacitinib Can Be Vaccinated for Shingles, Study Finds

News

Older rheumatoid arthritis (RA) patients being treated with tofacitinib responded well when given a live virus vaccine to prevent shingles, experiencing no clinical complications after vaccination, a new study reports. The findings are ... Read more

November 16, 2015November 16, 2015

Boehringer Enrolls RA Patients for Phase 3 Trial of Adalimumab Equivalent

News

Boehringer Ingelheim, one of the largest producers of biologic medicines in the world, recently announced that it has completed enrolling patients for its pivotal Phase 3 clinical trial (NCT02137226) evaluating BI-695501, a biosimilar drug ... Read more

November 11, 2015November 11, 2015

Phase 3 Rheumatoid Arthritis Study Raises Possibility of New Drug Treatment

News

Eli Lilly and Incyte Corporation recently presented comprehensive results from a pivotal Phase 3 clinical trial, RA-BEAM, evaluating baricitinib in the treatment of rheumatoid arthritis (RA). The data were presented during ... Read more

November 7, 2015November 13, 2015

Rheumatoid Arthritis Drug Eases Inflammation in Early Trial

News

Compugen Ltd., a leading drug discovery company and first-in-class biologics developer, recently disclosed data from its translational trial supporting the use of CGEN-15001 for the potential treatment of patients with a diagnosis of ... Read more

November 4, 2015November 4, 2015

In RA Pilot Study, Atacicept in Combination with Rituximab Shows No Clinical Benefits

News

Results from a recently pilot study published in the journal Arthritis & Rheumatology showed that in patients with rheumatoid arthritis (RA), atacicept combined with rituximab had no new safety issues but ... Read more

October 2, 2015October 5, 2015

AbbVie Announces ABT-494 Met Primary Endpoint in Two Phase II Studies In Severe Rheumatoid Arthritis Patients

News

AbbVie recently announced positive data from two Phase II studies that evaluated the company’s selective JAK1 inhibitor, called ABT-494, in patients with rheumatoid arthritis (RA) with an inadequate response to either methotrexate or ... Read more

September 23, 2015September 23, 2015

Depression and Anxiety Predict Treatment Response and Health Outcomes in Rheumatoid Arthritis

News

Depression and anxiety are highly prevalent in rheumatoid arthritis (RA) patients, with a recent meta-analysis reporting a 16.8% prevalence of depression, diagnosed via clinical interview. There is evidence to suggest a ... Read more

September 16, 2015September 16, 2015

High BMI Associated With Reduced Risk of Future Rheumatoid Arthritis in Men

News

Results from a recent study published in the journal Rheumatology showed that a high body mass index (BMI) was associated with a reduced risk of future rheumatoid arthritis (RA) in ... Read more

August 28, 2015August 28, 2015

Effectiveness of Oral Versus Subcutaneous Methotrexate for Early Rheumatoid Arthritis

News

Results from a recent study published in the BMJ journal showed that initial treatment with subcutaneous methotrexate is associated with lower rates of treatment changes, no difference in toxicity and some improvements ... Read more